Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares traded up 1% on Tuesday . The company traded as high as $4.79 and last traded at $4.67. 577,327 shares were traded during trading, a decline of 69% from the average session volume of 1,875,340 shares. The stock had previously closed at $4.72.

ACHN has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Robert W. Baird cut Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research report on Thursday, August 10th. Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Chardan Capital cut their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.50.

The company’s market capitalization is $641.41 million. The company’s 50-day moving average price is $4.50 and its 200 day moving average price is $4.21.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). During the same quarter in the prior year, the firm earned ($0.14) earnings per share. On average, equities research analysts forecast that Achillion Pharmaceuticals, Inc. will post ($0.66) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its stake in shares of Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 800 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Achillion Pharmaceuticals by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after purchasing an additional 2,850 shares during the last quarter. Bank of Montreal Can lifted its holdings in Achillion Pharmaceuticals by 6.4% during the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 3,410 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Achillion Pharmaceuticals by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 3,827 shares during the period. Finally, SG Americas Securities LLC boosted its stake in Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 4,144 shares during the period. Institutional investors own 74.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Trading -1% Higher” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/achillion-pharmaceuticals-inc-achn-trading-1-higher/1605981.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.